


## CLAIMS

1. (Currently Amended) Deoxynojirimycin analogue, or a pharmaceutically acceptable salt thereof, having the general structure (I)



wherein R<sub>1</sub>-R<sub>5</sub> each independently comprise H or (CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub> or X; n is 0-9

R<sub>6</sub> comprises H, CH<sub>2</sub>OH or CH<sub>2</sub>OX;

~~M~~m is 0 or 1;

~~N~~ is ~~0-9~~;

a, b, c, d, e are chiral ~~centra~~centers having an R or S configuration;

and X comprises a large hydrophobic moiety and a spacer, whereby the hydrophobic moiety is linked through the spacer to the nitrogen atom or carbon atom concerned, and wherein the large hydrophobic moiety is derived from a polycyclic alcohol containing three or more rings each sharing two or more carbon atoms with ~~another~~one of the other rings and is capable of inserting in lipid bilayers.

2. (original) Deoxynojirimycin analogue, or a pharmaceutically acceptable salt thereof, according to claim 1, wherein the large hydrophobic moiety is linked to said nitrogen atom of the deoxynojirimycin by means of a spacer comprising an alkoxy polyalkylene or polyalkylene chain of from 3 to 8 carbon atoms.

3. (previously presented) Deoxynojirimycin analogue, or a pharmaceutically acceptable salt

thereof, according to claim 1, wherein the large hydrophobic moiety is derived from a compound selected from the group consisting of adamantanemethanol, cholesterol,  $\beta$ -cholestanol, adamantanol and 9-hydroxyphenanthrene.

4. (previously presented) Deoxynojirimycin analogue, or a pharmaceutically acceptable salt thereof, according to claim 1, having the ido-configuration.

5. (original) Deoxynojirimycin analogue comprising ido-N-(5-adamantane-1-yl-methoxy pentyl)deoxynojirimycin, or a pharmaceutically acceptable salt thereof.

6. (Currently Amended) A method of treating a disease or condition involving increased levels of glucosylceramide and glucosphingolipids comprising administering an effective amount of a Deoxynojirimycin analogue according to claim 1 for use in the treatment of a disease involving increased levels of glucosyleceramide and glucosphingolipidsto a person in need thereof.

7. (Currently Amended) A method of treating a disease or condition involving increased levels of glucosylceramide glucosphingolipids and glucosidases comprising administering an effective amount of a Deoxynojirimycin analogue according to claim 1 for use in the treatment of a disease involving increased levels of glucosyleceramide, glucosphingolipids and glucosidases to a person in need thereof.

8. (Currently Amended) ~~Deoxynojirimycin analogue according to~~ The method of claim 6 ~~for use in the treatment wherein the disease is of~~ Gaucher disease.

9. (Currently Amended) ~~The method of~~ Deoxynojirimycin analogue according to claim 6 ~~for use in the treatment of~~ wherein the disease is an inflammatory disease.

10. (Currently Amended) The method of ~~Deoxynojirimycin analogue according to~~ claim 6 ~~for use~~

~~in the treatment of~~wherein the condition is hyperpigmentation and/or an inflammatory skin conditionscondition.

11. (Currently Amended) ~~The method of~~Dexynojirimycin analogue according to claim 6 for use ~~in the treatment of~~wherein the disease is a fungal disease.

12. (Currently Amended) ~~The method of~~Dexynojirimycin analogue according to claim 6 for use ~~in the treatment of~~wherein the condition is overweight and/or obesity.

13. (Currently Amended) ~~The method of~~Dexynojirimycin analogue according to claim 6 for use ~~in the treatment of~~wherein the disease is a lysosomal storage disorders.

14. (Currently Amended) ~~The method of~~Dexynojirimycin analogue according to claim 6 for use ~~in the treatment of~~wherein the condition is melanoma and/or a other tumors.

15. (Currently Amended) ~~The method of~~Dexynojirimycin analogue according to claim 6 for use ~~in the treatment of a~~wherein the disease is a microbacterial infection.

16. (Currently Amended) ~~The method of~~Dexynojirimycin analogue according to claim 7 for use ~~in the treatment of~~wherein the condition is insulin resistance.

17. (Currently Amended) Pharmaceutical composition comprising a ~~deoxynojirimycin~~ deoxynojirimycin analogue, or pharmaceutically acceptable salt thereof, according to claim 1 and a pharmaceutically acceptable carrier.

18. (Currently Amended) Method of treatment of an individual suffering from a disease selected from the group consisting of insulin resistance, ~~Gaucher~~ Gaucher disease, inflammatory diseases, hyperpigmentation and/or inflammatory skin conditions, overweight and obesity, lysosomal

storage disorders, fungal diseases, melanoma and other tumors, and microbacterial infections, comprising administering to said individual an effective amount of the pharmaceutical composition according to claim 17.

---